XML 31 R42.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Summary of Significant Accounting Policies - Additional Information (Details) (USD $) | 3 Months Ended |
--- | --- | ---
Mar. 31, 2015 Segment Entity | Mar. 31, 2014 | Dec. 31, 2014 Entity
Organization And Significant Accounting Policies [Line Items] |  |  |
Research and development commitments with third parties not incurred | $ 6,828,000 xon_ResearchAndDevelopmentCommitmentsNotYetIncurred |  | $ 2,183,000 xon_ResearchAndDevelopmentCommitmentsNotYetIncurred
Maturity period of liquid investment | 3 months |  |
Cash equivalent investments in highly liquid money market accounts | 87,768,000 us-gaap_MoneyMarketFundsAtCarryingValue |  | 16,598,000 us-gaap_MoneyMarketFundsAtCarryingValue
Number of collaborators over which the Company has significant influence | 2 xon_NumberOfCollaborators |  | 2 xon_NumberOfCollaborators
Fair value of financial assets measured at fair value on a recurring basis | 387,188,000 us-gaap_AssetsFairValueDisclosure |  | 280,497,000 us-gaap_AssetsFairValueDisclosure
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities | 115,454,000 us-gaap_FairValueOptionChangesInFairValueGainLoss1 | 21,922,000 us-gaap_FairValueOptionChangesInFairValueGainLoss1 |
Variable interest entities, risk of loss | 192,228,000 us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount |  | 0 us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount
Percentage of recognized income tax positions | 50.00%xon_IncomeTaxBenefitRecognitionCriteriaPercentageThreshold |  |
Number of segment | 1 us-gaap_NumberOfOperatingSegments |  |
Revenues | 33,849,000 us-gaap_Revenues | 7,854,000 us-gaap_Revenues |
Foreign Countries |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Long-lived assets | 82,133,000 us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember |  | 17,100,000 us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember
Revenues | 1,290,000 us-gaap_Revenues / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember | 0 us-gaap_Revenues / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember |
Equity Securities |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Fair value of financial assets measured at fair value on a recurring basis | 294,922,000 us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember |  | 164,889,000 us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember
Oragenics, Inc. |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Company's ownership percentage | 22.40%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |  | 24.40%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember
Oragenics, Inc. | Equity Securities |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Fair value of financial assets measured at fair value on a recurring basis | 8,128,000 us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |  | 7,192,000 us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities | 936,000 us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember | 710,000 us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
ZIOPHARM Oncology, Inc. |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Company's ownership percentage | 13.90%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |  | 15.70%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember
ZIOPHARM Oncology, Inc. | Equity Securities |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Fair value of financial assets measured at fair value on a recurring basis | 192,032,000 us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |  | 83,099,000 us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities | $ 96,334,000 us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember | $ 3,934,000 us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
Minimum |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Weighted Average Useful Life (Years) | 2 years |  |
Minimum | Leasehold Improvements |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Property plant and equipment, useful life | 1 year |  |
Maximum |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Weighted Average Useful Life (Years) | 14 years |  |
Maximum | Leasehold Improvements |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |
Property plant and equipment, useful life | 14 years |  |

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612 + Details
Name: | us-gaap_FairValueOptionChangesInFairValueGainLoss1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 + Details
Name: | us-gaap_MoneyMarketFundsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 + Details
Name: | us-gaap_NoncurrentAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=28200181&loc=d3e5728-111685 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=28200181&loc=d3e5747-111685 + Details
Name: | us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Original maturity period for highly liquid investments to be considered cash equivalent, maximum + References No definition available. + Details
Name: | xon_HighlyLiquidInvestmentMaximumMaturityPeriod
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Likelihood of realization percentage used in determining value of recognized income tax positions. + References No definition available. + Details
Name: | xon_IncomeTaxBenefitRecognitionCriteriaPercentageThreshold
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of collaborators over which the entity has significant influence, as it relates to determination of equity method investments. + References No definition available. + Details
Name: | xon_NumberOfCollaborators
Namespace Prefix: | xon_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | xon_OrganizationAndSignificantAccountingPoliciesLineItems
Namespace Prefix: | xon_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Portion of commitments related to research and development arrangements with third parties which has not yet been incurred. + References No definition available. + Details
Name: | xon_ResearchAndDevelopmentCommitmentsNotYetIncurred
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=xon_ForeignCountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |